Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Cecilia BrownPrint | November 23, 2022
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Read More
Leah SherwoodMyelodysplastic Syndromes | November 8, 2022
Venetoclax and azacitidine in R/R MDS demonstrated a manageable safety profile with meaningful clinical benefits...
Leah SherwoodMyelodysplastic Syndromes | November 8, 2022
Further development of BI 836858 was discontinued after it failed to elicit a response in transfusion-dependent.
Leah SherwoodMyelodysplastic Syndromes | November 8, 2022
Azacitidine may be a treatment option for patients with SAID associated with MDS and CMML.
Kerri FitzgeraldMyelodysplastic Syndromes | October 19, 2022
A prospective study failed to confirm the general predictive value of a biomarker-driven prediction model.
Kerri FitzgeraldMyelodysplastic Syndromes | October 19, 2022
HLA-matched sibling donors are the preferred transplant choice for MDS.
Kerri FitzgeraldMyelodysplastic Syndromes | October 4, 2022
A study showed "unexpected" results related to race and MDS survival...
Leah SherwoodMyelodysplastic Syndromes | October 4, 2022
Nearly a third (30%) of patients with higher-risk MDS have an overexpression of the RARA gene...
Leah SherwoodMyelodysplastic Syndromes | October 4, 2022
The classification process is mainly based on two processes, class discovery and class prediction...
Leah SherwoodMyelodysplastic Syndromes | October 3, 2022
Phillip Scheinberg, MD, PhD, discusses myelodysplastic syndromes at the 2022 SOHO Annual Meeting...
Leah SherwoodMyelodysplastic Syndromes | October 2, 2022
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
Leah SherwoodMyelodysplastic Syndromes | October 2, 2022
Blood Cancers Today interviewed Dr. Diez-Campelo after her presentation titled, “Treatment of Lower Risk MDS.”
Leah SherwoodMyelodysplastic Syndromes | October 2, 2022
Researchers retrospectively assessed 135 untreated patients with MDS who later developed HMA-F...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Kerri FitzgeraldMyelodysplastic Syndromes | September 30, 2022
Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting...
Leah SherwoodMyelodysplastic Syndromes | September 30, 2022
The outcomes of AML transformation after HMA-failure MDS remain extremely poor...
Leah SherwoodMyelodysplastic Syndromes | September 30, 2022
Azacitidine is the current standard of care, and magrolimab is a monoclonal antibody blocking CD47 expression...
Kerri FitzgeraldMyelodysplastic Syndromes | September 29, 2022
During the 2022 SOHO Annual Meeting, Jacqueline S. Garcia, MD, discussed immunotherapies for myelodysplastic syndromes...
Leah SherwoodMyelodysplastic Syndromes | September 29, 2022
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Leah SherwoodMyelodysplastic Syndromes | September 28, 2022
Dr. Garcia-Manero talks about what a “total approach” to MDS means to him...
Advertisement
Editorial Board

Advertisement